Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994368 · ClinicalTrials.gov registry record
"Natural History" Study of Choroideremia
A clinical trial, sponsored by 4D Molecular Therapeutics.
- Terminated
- Registry status
- 57
- Enrollment target
NCT02994368: Clinical Trial study, sponsored by 4D Molecular Therapeutics.
NCT02994368 is a clinical trial that was terminated before completion, run by 4D Molecular Therapeutics. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02994368 was terminated before completion, sponsored by 4D Molecular Therapeutics.
- TERMINATED
- Registry status
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and participant-reported visual problems
Primary Outcome
A variety of psychophysical, anatomical and image-based endpoints
Interventions
- OTHER Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2016-12 |
| Est. Completion | 2021-10 |
Why NCT02994368 stopped before completion
NCT02994368 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Observation is the first listed.
NCT02994368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02994368 about?
NCT02994368 is a clinical study titled ""Natural History" Study of Choroideremia". The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and participant-reported visual problems
What is the current status of trial NCT02994368?
This trial is currently terminated. The enrollment target is 57 participants. The study started on 2016-12. Estimated completion is 2021-10.
What interventions are being tested in trial NCT02994368?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT02994368?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia